CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.
Note: The pCODR Provincial Advisory Group, PAG, has submitted a Request for Advice for the Final Recommendation for this drug and indication originally posted on March 7, 2013. The original axitinib (Inlyta) pCODR review can be found on the Inlyta for metastatic renal cell carcinoma (mRCC) details page: https://www.cadth.ca/inlyta-metastatic-renal-cell-carcinoma-mrcc-details.
| Project Number | PA0001-000 |
|---|---|
| Brand Name | Inlyta (RFA) |
| Generic Name | Axitinib |
| Tumour Type | Genitourinary |
| Indication | Metastatic Renal Cell Carcinoma |
| Review Status | Complete |
| Pre Noc Submission | |
| NOC Date | |
| Manufacturer | Pfizer Canada Inc. |
| Sponsor | pCODR Provincial Advisory Group |
| Submission Date | April 18, 2017 |
| Submission Type | Request for Advice |
| Prioritization Requested | |
| Stakeholder Input Deadline ‡ | May 2, 2017 |
| pERC Meeting | June 16, 2017 |
| Clarification | Please note that the June pERC meeting was conducted over two days. The target for the posting of pERC Initial Recommendation remains as June 29, 2017. |
| Final Recommendation Issued (target date) | June 29, 2017 |
| Notification to Implement Issued | June 30, 2017 |
| Therapeutic Area | Metastatic Renal Cell Carcinoma |
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.
